7 news items
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
IRWD
30 May 24
as several earlier stage assets. Building upon our history of GI innovation, we keep patients at the heart of our R&D and commercialization efforts
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
IRWD
21 May 24
at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs. Founded in 1998
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
IRWD
9 May 24
of commercial and research and development ("R&D") expenses and excluding the gross-to-net change in estimate, was $175.6 million in the first quarter
Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
IRWD
6 May 24
. Building upon our history of GI innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
IRWD
1 May 24
history of GI innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address
lxde1sw8lyqxr fzkwr55vmu68n57xk
IRWD
25 Apr 24
patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs
8gj8qruwm4ziwmucnssjqod13jz8dwdt3n178sm12e
IRWD
28 Mar 24
earlier stage assets. Building upon our history of GI innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce
- Prev
- 1
- Next